The role of α1-adrenoceptor antagonists in the treatment of prostate and other cancers by Batty, Mallory et al.
Bond University
Research Repository
The role of alpha 1-adrenoceptor antagonists in the treatment of prostate and other cancers
Batty, Mallory; Pugh, Rachel; Rathinam, Ilampirai; Simmonds, Joshua; Walker, Edwin;
Forbes, Amanda; Anoopkumar-Dukie, Shailendra; McDermott, Catherine; Spencer, Briohny;
Christie, David; Chess-Williams, Russ
Published in:
International Journal of Molecular Sciences
DOI:
10.3390/ijms17081339
Published: 16/08/2016
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Batty, M., Pugh, R., Rathinam, I., Simmonds, J., Walker, E., Forbes, A., ... Chess-Williams, R. (2016). The role
of alpha 1-adrenoceptor antagonists in the treatment of prostate and other cancers. International Journal of
Molecular Sciences, 17(8), 1-26. https://doi.org/10.3390/ijms17081339
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 10 May 2019
 International Journal of 
Molecular Sciences
Review
The Role of α1-Adrenoceptor Antagonists in the
Treatment of Prostate and Other Cancers
Mallory Batty 1,†, Rachel Pugh 1,†, Ilampirai Rathinam 1,†, Joshua Simmonds 1,†,
Edwin Walker 1,†, Amanda Forbes 2,†, Shailendra Anoopkumar-Dukie 1,3,
Catherine M. McDermott 2, Briohny Spencer 1, David Christie 1,2 and Russ Chess-Williams 2,*
1 School of Pharmacy, Griffith University, Gold Coast, QLD 4222, Australia;
mallory.batty@griffithuni.edu.au (M.B.); rachel.pugh@griffithuni.edu.au (R.P.);
ilampirai.rathinam@griffithuni.edu.au (I.R.); joshua.simmonds@griffithuni.edu.au (J.S.);
edwin.walker@griffithuni.edu.au (E.W.); s.dukie@griffith.edu.au (S.A.-D.); b.spencer@griffith.edu.au (B.S.);
David.Christie@genesiscare.com.au (D.C.)
2 Centre for Urology Research, Faculty of Health Sciences and Medicine, Bond University, Robina, QLD 4226,
Australia; amanda.forbes@student.bond.edu.au (A.F.); camcderm@bond.edu.au (C.M.M.)
3 Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD 4222, Australia
* Correspondence: rchesswi@bond.edu.au; Tel.: +61-7-5595-4420
† These authors contributed equally to this work.
Academic Editor: William Chi-shing Cho
Received: 6 July 2016; Accepted: 8 August 2016; Published: 16 August 2016
Abstract: This review evaluates the role of α-adrenoceptor antagonists as a potential treatment of
prostate cancer (PCa). Cochrane, Google Scholar and Pubmed were accessed to retrieve sixty-two
articles for analysis. In vitro studies demonstrate that doxazosin, prazosin and terazosin (quinazoline
α-antagonists) induce apoptosis, decrease cell growth, and proliferation in PC-3, LNCaP and DU-145
cell lines. Similarly, the piperazine based naftopidil induced cell cycle arrest and death in LNCaP-E9
cell lines. In contrast, sulphonamide based tamsulosin did not exhibit these effects. In vivo data was
consistent with in vitro findings as the quinazoline based α-antagonists prevented angiogenesis and
decreased tumour mass in mice models of PCa. Mechanistically the cytotoxic and antitumor effects
of the α-antagonists appear largely independent of α 1-blockade. The proposed targets include:
VEGF, EGFR, HER2/Neu, caspase 8/3, topoisomerase 1 and other mitochondrial apoptotic inducing
factors. These cytotoxic effects could not be evaluated in human studies as prospective trial data
is lacking. However, retrospective studies show a decreased incidence of PCa in males exposed to
α-antagonists. As human data evaluating the use of α-antagonists as treatments are lacking; well
designed, prospective clinical trials are needed to conclusively demonstrate the anticancer properties
of quinazoline based α-antagonists in PCa and other cancers.
Keywords: α1-adrenoceptor antagonist; prostate cancer; cytotoxicity
1. Introduction
Prostate cancer is the most commonly diagnosed male cancer in the world [1]. In Australia,
prostate cancer account for approximately 30% of all newly diagnosed cancers and is the second most
common cause of cancer-specific death in men [2]. Early stage prostate cancer is highly manageable
using definitive radical prostatectomy and/or radiotherapy techniques. However, an estimated
one-fifth of men will experience disease recurrence following curative treatment modalities [3–5]
and resort to first-generation androgen deprivation therapies for long-term management of their
disease. Unfortunately, progression after androgen deprivation therapy indicates the transition to
castrate-resistant prostate cancer (CRPC), which is considered to be both inevitable and incurable.
Although there has been significant progress in the CRPC treatment landscape (e.g., enzalutamide,
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abiraterone, cabazitaxel), there are no currently available therapies which provide a survival benefit
greater than twelve months [6–10]. Therefore, there is an urgent need for novel agents to improve the
oncological and survival outcomes for these last-resort patients. One such modality may be through
the use of α1-adrenoceptor (ADR) antagonists.
Adrenoceptors (also known as adrenergic receptors) are members of the G protein-coupled
receptor (GPCR) superfamily, which can be further broken down into α and β subtypes with several
homologous isoforms including α-1 (A, B, and D), -2 (A, B, and C), and β-1, 2, and 3 [11]. While
all adrenergic receptors play an important role in regulating human tissue homeostasis, the focus of
this review will primarily cover α1-ADRs in the human prostate. α1-ADRs are largely found in the
stromal region of the human prostate, with few α1-ADR receptors localised in the prostate epithelium.
Although, the α1A-ADR isoform (previously identified as α1C) is known to make up approximately
70% of the prostatic α1-ADRs [12], recent evidence suggests that the distribution of α1-ADR isoforms
(A, B and D) change with advancing age and are correlated with the subsequent onset of prostatic
hyperplasia [13]. Likewise, receptor localisation and expression appears to be altered in prostate
cancer tissues. Unlike normal prostate epithelium which expresses few α1-ADRs, prostate cancer
epithelia have been reported to express functional α1A-ADR [14,15], as well as increased mRNA levels
of α1B and α1D isoforms [16]. It remains unclear whether α1-ADRs have a role in promoting prostate
carcinogenesis remains unclear. However, α1-ADRs have been identified to play a role in cellular
proliferation in vitro [14,17–19] and therefore may be exploited for treatment of neoplasms.
α1-ADR antagonists (referred to here as “α-antagonists”) are commonly used in clinical practice
to treat hypertension, and more recently, the urodynamic symptoms associated with benign prostate
hyperplasia (BPH). In BPH, α-antagonists block receptor activation to relax the prostatic smooth muscle
thereby improving rate of urine flow and other associated lower-urinary tract symptoms (LUTS) [20,21].
There are regional differences in the commonly prescribed α-antagonists for BPH. In the United States,
the non-selective doxazosin and terazosin are the most commonly prescribed α1-blockers due to
their relatively long half-life [22,23] and clinically significant improvement in BPH-related LUTS.
Furthermore, these drugs have been associated with fewer adverse drug-related cardiovascular side
effects, compared to prazosin [24]. However, in Australia, the short acting and non-selective prazosin
is clinically favored over other α-antagonists primarily due to the rapid mitigation of LUTS. The highly
selective tamulosin, also offer significant reduction in BPH-related LUTS symptoms, however, at a cost
of ejaculatory dysfunction making this α1-ADR antagonists undesirable for some men [24].
In the late 1990s, monotherapy with α-antagonists was shown to provide long-term clinical
benefits that could not be explained solely by acute prostatic relaxation [25–27]. In support of these
findings, a more recent study uncovered a large proportion of men (70%) experienced continued
improvement of BPH-associated LUTS following discontinuation of α-antagonists [28]. Subsequent
studies over the next sixteen years have identified that some of these drugs possess novel cytotoxic
actions in diseased prostates, including prostate and other cancers. Despite the plethora of original
papers investigating the anticancer effects of these drugs, only few systematic reviews since the early
2000s have been carried out to colligate the more recent published findings [29–33]. Therefore, the
aim of this systematic literature review is to analyse the current evidence for the use of α-antagonists
as potential treatment options for prostate cancer (PCa). Specifically, this review will colligate the
anticancer mechanisms of α-antagonists, evaluate the evidence supporting clinical anticancer efficacy
of these drugs in PCa, and evaluate the evidence for use of these drugs in other cancers.
2. Results
Pubmed, Google Scholar and Cochrane databases were accessed to retrieve articles. The search
terms used to find the relevant articles were separated into three categories: terms that describe the
α-antagonists, the target tissue and the action of the drugs (Table A1). Four hundred and ninety-six
articles were identified using the inclusion criteria by searching three databases: Cochrane, Pubmed
and Google Scholar. After exclusion criteria were applied, sixty-two relevant articles were obtained,
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consisting of fifty-four original manuscripts and eight review articles. (Figure A1). Of the fifty-four
research articles identified only four studies examined the role of α-antagonists in PCa development in
humans (Table 1). The majority focused on the cytotoxic and anti-tumour activity of α-antagonists
in vitro and in animal models (Table 2). These retrospective cohort and observational human studies
examined the effects of both quinazoline and non-quinazoline α-antagonists, but show only an overall
decreased incidence of PCa. Two additional researchers replicated the search which returned identical
results, validating the method used, for robustness.
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Table 1. Clinical-based studies investigating the effect of α1-antagonists on prostate cancer (PCa).
Author Title Drug Results Study Type
Keledjian, K. et al. [34]
Reduction of human prostate tumor
vascularity by the α1-adrenoceptor
antagonist terazosin
Terazosin
Increased apoptotic index in prostate carcinoma after terazosin treatment.
Reduction in prostate tumour vascularity in terazosin-treated BPH patients.
Patients were treated for 6–11 months
Retrospective Cohort study
Harris, A. et al. [35]
Effect of α1-adrenoceptor antagonist
exposure on prostate cancer incidence:
an observational cohort study
Doxazosin & Terazosin
4070 men were treated with α-antagonists for Benign prostatic hyperplasia
or hypertension or HTN. The incidence of PCa among treated men vs.
untreated men was 1.65% and 2.41% respectively. Data showed 7.6 fewer
cases developed per 1000 exposed men
Observational Cohort study
Yamada, D. et al. [36]
Reduction of prostate cancer incidence by
naftopidil, an α1-adrenoceptor
antagonist and transforming growth
factor-β signalling inhibitor
Naftopidil & Tamsulosin PCa incidence was significantly lower in men treated with naftopidil for≥3 months compared to men treated with tamsulosin. (p = 0.035) Retrospective Cohort study
Bilbro, J. et al. [37] Therapeutic value of quinazoline-basedcompounds in prostate cancer
Doxazosin, terazosin and
other quinazolines
Patients treated with α1-antagonists: doxazosin and terazosin, at the
Markey Cancer centre had reduced risk of developing PCa Retrospective Cohort study
Table 2. Summary of identified studies investigating the anticancer effect of α-antagonists.
Ref. Author Title Study Type Cancer Type Drugs Findings (Original Studies)
[29] Nishizaki, T. et al.
1-[2-(2-Methoxyphenylamino)
ethylamino]-3-(naphthalene-1-yloxy)
propan-2-ol may be a promising
anticancer drug
Review NA NA
[30] Kyprianou, N. et al.
Apoptosis induction by doxazosin
and other quinazoline
α1-adrenoceptor antagonists: a new
mechanism for cancer treatment?
Review NA NA
[31] Patane, S. et al.
Insights into cardio-oncology:
Polypharmacology of
quinazoline-based
α1-adrenoceptor antagonists
Review NA NA
[32] Desiniotis, A. et al.
Advances in the design and
synthesis of prazosin derivatives
over the last ten years
Review NA NA
[33] Tahmatzopoulos, A.et al.
The role of α-blockers in the
management of prostate cancer Review NA NA
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Table 2. Cont.
Ref. Author Title Study Type Cancer Type Drugs Findings (Original Studies)
[34] Kyprianou, N. et al.
Suppression of human prostate
cancer cell growth by
α1-adrenoceptor antagonists
Doxazosin and terazosin via
induction of apoptosis
In vitro, in vivo
(mice)
Prostate Cancer
(PC-3 and DU145)
Doxazosin, terazosin,
tamsulosin,
phenoxy-benzamine
Doxazosin and terazosin induced apoptosis in prostate epithelial and
smooth muscle cells in patients with BPH, without affecting rate of cell
proliferation in PCa cells.
This effect could not be prevented by irreversible inhibition of
α1-adrenoceptors (phenoxybenzamine), indicating an in vitro toxicitity
occurs via an α-receptor independent mechanism. Doxazosin
administration (at tolerated pharmacologically relevant doses) in SCID
mice resulted in a significant inhibition of PC-3 tumour growth,
presumably via induction of apoptosis.
[35] Pan, S. et al.
Identification of apoptotic and
antiangiogenic activities of terazosin
in human prostate cancer and
endothelial cells
In vitro, in vivo
(mice)
PCa PC-3 &
endothelial
HUVEC cells
Terazosin
It was found that terazosin induced apoptosis in PC-3 and human benign
prostatic cells (IC50 > 100 µM), and possessed potent anti-angiogenic effect
in endothelial cells compared to PCa cells. Terazosin (IC50 of 7.9 µM)
significantly inhibited VEGF-induced angiogenesis and endothelial tube
formation in nude mice, demonstrating that terazosin had a more potent
anti-angiogenic than cytotoxic effects. Terazosin also effectively inhibited
vascular endothelial growth factor induced proliferation and tube
formation in cultured human umbilical vein endothelial cells (IC50 9.9
and 6.8 µM, respectively). Doxazosin, but not tamsulosin, mimicked these
effects and the anti-tumour effects of these drugs were determined to
occur independent of α1-adrenoceptor antagonizing activity.
[36] Walden, P. et al.
Induction of anoikis by Doxazosin in
prostate cancer cells is associated
with activation of caspase-3 and
a reduction of focal adhesion kinase
In vitro PCa(PC-3 and LNCaP) Doxazosin
Doxazosin induced changes in morphology consistent with anoikis in
both benign and cancerous prostatic cells (rounding up of cells,
DNA-degradation in the nucleus, cell shrinkage, the appearance of
vacuoles, and cell detachment from the tissue culture plate) and increased
caspase-3 activity. The increase of caspase-3 activity by doxazosin
promotes anoikis and, subsequently, apoptosis of cancer cells. Treatment
of PC-3 cells with doxazosin significantly reduced the protein levels of
anti-anoikis kinase, FAK, but did not significantly affect the levels of ILK.
Norepinephrine had no effect on doxazosin-induced cell morphology or
caspase-3 activity, indicating that the apoptotic/anoikis effects of
doxazosin result from mechanism that is a1-adrenoceptor independent.
[37] Benning, C. et al.
Quinazoline-derived
α1-adrenoceptor antagonists induce
prostate cancer cell apoptosis via an
α1-adrenoceptor-independent action
In vitro Prostate cancercells Doxazosin, terazosin
Transfection-mediated overexpression of α1-adrenoreceptors in human
prostate cancer cells, DU-145 (AR-independent, and reportedly lack of
adrenoceptors), did not alter the ability of prostate cancer cells to undergo
apoptosis in response to quinazolines. These findings indicate that
apoptotic activity of quinazoline-based α1 adrenoceptor antagonists
(doxazosin and terazosin) in prostate cancer cells is independent of
α1-adrenoceptor antagonism.
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Ref. Author Title Study Type Cancer Type Drugs Findings (Original Studies)
[38] Kyprianou, N.
Doxazosin and terazosin suppress
prostate growth by inducing
apoptosis: clinical significance
Review, in vitro,
in vivo (mice)
PC-3, DU-145 and
SMC-1 Doxazosin, terazosin
Doxazosin and terazosin significantly reduced the viability of PC-3 and
LNCaP cells by inducing caspase-3 mediated apoptosis in a dose
dependent manner, however only doxazosin induced significant death of
PCa cells. Doxazosin (and not terazosin) significantly affect the rate of
proliferation of PCa cells. Irreversible inhibition with phenoxybenzamine
did not abolish the apoptotic effect of doxazosin or terazosin against PCa
or SMC cells, indicating the cytotoxic effects occurred via an
α1-independent mechanism. Oral treatment with doxazosin resulted in
significant decrease in tumour volume of PCa xenografts compared to
controls, presumably via induction of apoptosis.
[39] Arencibia, J. et al.
Doxazosin induces apoptosis in
LNCaP prostate cancer cell line
through DNA binding and
DNA-dependent protein
kinase down-regulation
In vitro LNCaP Doxazosin
Doxazosin induced dose-dependent LNCaP cytotoxicity and apoptosis,
which could not be prevented by phenoxybenzamine, indicating
an α1-adrenoceptor independent cytotoxicity. Microarray analysis
following doxazosin treatment (8–24 h, 20 µM) identified 70–92
deregulated genes, including several involved in cell-cycle control and
drug response, and a few related to other cellular processes such as
apoptosis or angiogenesis. An inverse correlation was observed with
doxazosin concentration and topoisomers, suggesting that topoisomerase
I is inhibited by the binding of doxazosin to DNA. Thus, doxazosin could
cause DNA damage, resulting in apoptotic cell death.
[40] Siddiqui, E. et al.
Growth inhibitory effect of
Doxazosin on prostate and bladder
cancer cells. Is the serotonin receptor
pathway involved?
In vitro PCa PC-3, bladdercancer HT1376 Doxazosin
Doxazosin was found to significantly reduce PCa PC-3 and bladder cancer
HT1376 cell growth, which was partially prevented through pre-treatment
with 5HT or 5-HT1B. These findings may be related to the structural
similarity between subtype 1 serotonin and adrenergic receptors, and the
authors suggests that doxazosin displaces 5-HT from 5-HT receptors.
[41] Garrison, J. et al.
Doxazosin induces apoptosis of
benign and malignant prostate cells
via a death
receptor-mediated pathway
In vitro PC-3 and BPH1 Doxazosin
Doxazosin (24 h) causes a dose dependent loss of cell viability and
induces apoptosis in PC-3 and BPH1 cells 24 h after treatment.
After a short doxazosin treatment (6 h), several genes that play a critical
role in apoptosis were upregulated in PC-3 cells. In particular, doxazosin
was found to upregulate Bax mRNA transcription and induced caspase-8
mediated apoptosis.
[42] Lin, S. et al.
Prazosin displays anticancer activity
against human prostate cancers:
targeting DNA and cell cycle
In vitro, in vivo
(mice) Prostate Cancer Prazosin
Prazosin exhibited anti-proliferative activity superior to that of other
α-blockers. It induced G2 checkpoint arrest and subsequent apoptosis.
In PC-3 cells, prazosin increase in DNA strand breakage leading to Cdk1
inactivation and subsequent cell cycle arrest. In mice, prazosin
significantly reduced tumour mass in PC-3 derived cancer xenografts.
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Ref. Author Title Study Type Cancer Type Drugs Findings (Original Studies)
[43] Forbes, A. et al.
Relative cytotoxic potencies and cell
death mechanisms of
α-adrenoceptor antagonists in
prostate cancer cell lines
In vitro PCa PC-3, LNCaP
Prazosin Doxazosin,
terazosin, silodosin,
alfuzosin, tamsulosin
The relative potency order was prazosin = doxazosin > terazosin =
silodosin = alfuzosin> tamsulosin on both cell types, but LNCaP cells
were significantly more sensitive to these effects that PC-3 cells. Prazosin
and doxazosin increased levels of apoptosis and autophagy in both cell
lines. However, autophagy was found to play a paradoxical role by
contributing to survival of LNCaP and cytotoxicity of PC-3 cells.
Treatment with prazosin (30 µM) altered the expression of several cell
stress-related proteins: elevating phospho-p38α and reducing S6 kinase in
both cell lines. The expression of some proteins were differentially
affected in PC-3 and LNCaP cell; Akt and p27 increasing and HIF-1α
decreasing in LNCaP cells but not PC-3, while ADAMTS1 was increased
in PC-3 cells only. Phosphorylation of EphA2 was also reported to play
a role in doxazosin, but not prazosin, induced PC-3 cytotoxicity.
[44] Fernando, M. et al.
α1-Adrenergic receptor antagonists:
novel therapy for
pituitary adenomas
In vitro, in vivo
(mice) Pituitary tumour Doxazosin
Treatment with Doxazosin results in reduced phosphorylation and
down-regulation of NFκB. Decreased phosphorylated retinoblastoma and
PCNA expression, which resulted in cell cycle arrest at G0-G1. Doxazosin
treatment also increased cleaved caspase 3. In mice, the tumour mass was
lower in the doxazosin treated group. In contrast to current literature,
this study suggested that the cytotoxic activity of quinazoline-antagonists
was greater in cells that express α1a and 1b. In addition to apoptosis,
doxazosin treatment appeared to reduce the circulating ACTH level and
therefore may be useful for symptomatic relief.
[45] Youm, Y. et al.
Doxazosin-induced clusterin
expression and apoptosis in prostate
cancer cells
In vitro PCa PC-3 Doxazosin
Doxazosin-induced DNA fragmentation after 24 h treatment, and was
statistically significant after 48 h treatment of PC-3 cells. Clusterin
expression in PC-3 cells was 3-fold higher in doxazosin treated cells (9 h)
compared to untreated controls, and was maintained over 48 h. These
findings were found to be consistent with doxazosin-induced apoptosis.
Immunocytochemistry analysis (after 9 and 12 h treatment) demonstrated
the presence of clusterin in 7% and 18% of total cells respectively. At 24 h
treatment, clusterin protein was mainly observed in the cytoplasm and
rarely in the nuclei of healthy cells.
[46] Tahmatzopoulos, A.et al.
Maspin sensitizes prostate cancer
cells to Doxazosin-induced apoptosis In vitro PCa DU-145 Doxazosin
Maspin (tumour suppressor protein) was shown to increase sensitivity of
PCa DU-145 cells to doxazosin, by affect the migration and attachment of
malignant prostate cells to the ECM. Also caused mammary
MDA-MB-435 cells to undergo apoptosis via increased Bax and
caspase-3 activation.
[47] Partin, J. et al.
Quinazoline-based α1-adrenoceptor
antagonists induce prostate cancer
cell apoptosis via TGF-β signalling
and I κB α induction
In vitro PCa PC-3 Doxazosin,tamsulosin
Doxazosin, but not tamsulosin, was found to induce PC-3 apoptosis by
enhancing TGF-β1 signalling, and subsequently, downstream 1κBα.
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[48] Keledjian, K. et al.
Anoikis induction by quinazoline
based α1-adrenoceptor antagonists
in prostate cancer cells: antagonistic
effect of bcl-2
In vitro PCa PC-3
Doxazosin, terazosin,
tamsulosin (at
therapeutic doses)
Treatment of PC-3 cells with doxazosin or terazosin, but not tamsulosin,
resulted in significant down regulation of VEGF. Doxazosin also
promoted anoikis. However, these effect was reduced in PC-3s that
over-expressed Bcl-2 (an anoikis inhibiting factor). In these experimental
conditions, these drugs did not have any effect on HIF1-α expression.
[49] Liao, C. et al. Anti-angiogenic effects andmechanism of prazosin In vitro PCa and HUVEC Prazosin
Prazosin induced apoptosis in PCa and normal HUVEC cells via different
mechanisms, suggesting that prazosin-mediated anti-angiogenic activity
and differential modulation of apoptotic pathways are cell-type specific.
[50] Kim, S. et al.
Dual silencing of Hsp27 and c-FLIP
enhances doxazosin-induced
apoptosis in PC-3 prostate
cancer cells
In vitro PCa PC-3 Doxazosin
Apoptotic indices increased in a dose-dependent manner when doxazosin
was added. In basal conditions (+Hsp27/+c-FLIP), doxazosin (25 µM)
induced apoptosis in 52% of cells. In −Hsp27/+c-FLIP cells, apoptotic
activity increased to 68% of PC-3 cells. In the opposite case
(+Hsp27/−c-FLIP) the apoptotic index was 78%. Even greater number of
apoptotic cells were observed (92%) when both Hsp27 and c-Flip were
silence. These findings indicate that Hsp27 and c-FLIP play a protective
role against doxazosin induced cytotoxicity of PC-3 cells.
[51] Lee, S. et al.
Expression of heat shock protein 27
in prostate cancer cell lines
according to the extent of
malignancy and doxazosin treatment
In vitro PCa LNCaP, PC-3 Doxazosin
RT-PCR studies identified Hsp27 expression to be related to PCa
malignancy potential in vitro (e.g., Hsp27 > in PC-3 than LNCaP cells),
and was dose-dependently enhanced in some cell lines following
doxazosin treatment. Apoptotic cell death triggered by HSP27 siRNA is
greater in the androgen receptor-negative cell line PC-3 than in the
androgen receptor-positive cell line LNCaP.
[52] Cal, C. et al. Doxazosin: a new cytotoxic agent forprostate cancer? In vitro PCa DU145, PC-3
Doxazosin
adriamycin,
etoposide, paclitaxel.
DU-145 and PC3 were sensitive to doxazosin-mediated cytotoxicity,
which occurred in a dose- and time-dependent fashion. The combination
of doxazosin and adriamycin or etoposide resulted in significant
dose-dependent cytotoxic synergism. In contrast, the combination of
doxazosin and paclitaxel resulted in antagonistic activity, which was
enhanced with increasing concentrations of the drugs.
[53] Chang, K. et al.
Combined effects of terazosin and
genistein on a metastatic,
hormone-independent human
prostate cancer cell line
In vitro PCa DU-145 Terazosin, genistein
Terazosin or genistein alone inhibited cell growth in a dose-dependent
manner genistein (5 µ/mL) being more effective than terazosin (1
µ/mL—nontoxic dose). Combination treatment significantly increased
apoptosis in cells compared to genistein alone. The synergistic effects of
these drugs had a greater inhibitory effect the pro-survival Bcl-XL protein,
compared to either drug along. Genistein and the combination also were
reported to have an effect on angiogenesis-related proteins, causing a
significant decrease in VEGF165 mRNA and VEGF121 mRNA levels.
[54] Harris, A. et al.
Effect of α1-adrenoceptor antagonist
exposure on prostate cancer
incidence: an observational
cohort study
Observational
cohort PCa
Doxazosin and
Terazosin
Incidence of PCa in men exposed to quinazoline-based α-blockers (for
BPH or hypertension) was 1.65% whereas in unexposed men, incidence
was 2.41%. This indicates men who were exposed to quinazolines were
1.46 times lower relative risk of developing PCa, compared to unexposed
men. However, there was no association between quinazoline exposure
and overall patient survival.
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[55] Liu, C. et al.
Piperazine-designed
α1A/α1D-adrenoceptor blocker
KMUP-1 and Doxazosin provide
down-regulation of androgen
receptor and PSA in prostatic
LNCaP cells growth and specifically
in xenografts
In vitro, in vivo
(mice)
PCa: LNCaP, PC-3
and DU-145
Doxazosin and
KMUP-1
KMUP-1 and Doxazosin both inhibit LNCaP cell growth and
downregulate expression of AR and PSA. KMUP-1 is a Xanthine
derivative PDE inhibitor with α-blocking features. It also has a piperazine
moiety very similar to that seen in Doxazosin, naftopidil which is reported
to lead to its activity. KMUP-1 significantly inhibited LNCaP cell growth
and induced apoptosis in time and dose-dependent manner. KMUP-1 and
doxazosin further inhibited the expression of AR and PSA. Treatment of
LNCaP cells with KMUP-1 resulted in cell cycle arrest and apoptotic
activities, increasing p21 and p27 and decreasing expressions of cyclin D1,
cyclin E, cyclin dependent kinase (CDK) 4, CDK2 and CDK6. Moreover,
KMUP-1 activated p53, cleaved poly (ADP-ribose) polymerase and
caspase-3, but reduced the expression of Bcl-2. Regular administration of
KMUP-1 suppressed the LNCaP xenograft tumour growth in nude mice.
These evidences indicate that KMUP-1 and doxazosin inhibit LNCaP cell
growth and downregulate expression of AR and PSA. KMUP-1 might be
used as a chemoprevention agent for preventing the development of
prostate cancer without cardiovascular adverse effect of doxazosin.
[56] Ho, C. et al.
Repurposing of phentolamine as a
potential anticancer agent against
human castration-resistant prostate
cancer: A central role on
microtubule stabilization and
mitochondrial apoptosis pathway
In vitro PCa DU145, PC-3 Phentolamine,paclitaxel
Phentolamine induced anti-proliferative effects in PC-3 and Du-145,
two CRPC cell lines and p-glycoprotein overexpressing cells. This effect
was not significantly reduced in paclitaxel resistant cells. Phentolamine
induced mitotic arrest of the cell cycle and formation of hyperdiploid cells,
followed by an increase of apoptosis. Mitotic arrest was confirmed by
cyclin B1 up regulation, CDK1 activation and a dramatic increase of
mitotic protein phosphorylation. In vitro cellular identification
demonstrated that phentolamine, similar to paclitaxel, induced tubulin
polymerization and formation of multiple nuclei. The Data suggests that
phentolamine is a potential anti-cancer agent. It induces microtubule
assembly, leading to mitotic arrest of the cell cycle, which ‘in turn’ induces
subsequent mitochondrial damage, and activation of related apoptotic
signalling pathways in CRPC cells. Furthermore, the combination
between phentolamine and paclitaxel induces a synergistic apoptotic cell
death. Phentolamine has a simple chemical structure and is not P-gp
substrate. Optimization of phentolamine structure may also be a potential
approach for further development.
[57] Anglin, I. et al.
Induction of prostate apoptosis by
α1-adrenoceptor antagonists:
mechanistic significance of the
quinazoline component
Review
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[58] Keledjian, K. et al.
Doxazosin inhibits human vascular
endothelial cell adhesion, migration,
and invasion
In vitro HUVEC,endothelial cells Doxazosin
Doxazosin results in a dose-dependent loss of cell viability after 24 h of
treatment. At concentrations as low as 1 mM, 10% loss of cell viability is
observed and at 15 mM there is more than 30% cell death. There is also
significant increase in the number of apoptotic cells within 24 h of
exposure to doxazosin and a further increase after 48 h. Increased protein
expression of pro-caspase-3 was observed after 6 and 12 h of doxazosin
treatment. Doxazosin markedly suppresses VEGF—mediated endothelial
cell adhesion to fibronectin. HUVEC cells were wounded and 24 h
post-wounding, doxazosin treatment (15 mM) resulted in a dramatic
decrease in HUVEC cell migration in the absence or presence of
exogenous VEGF compared to control. Thus doxazosin can cause
suppression of VEGF-mediated cell migration. FGF-2, a potent angiogenic
factor, results in significant stimulation of HUVEC angiogenic response
that was suppressed by doxazosin treatment. TGF-b had no significant
impact on HUVEC-tube formation. Doxazosin treatment for 24 h resulted
in a significant downregulation of VEGF mRNA.
[59] Petty et al.
A small moleculre agonist of EphA2
receptor tyrosine kinase inhibits
tumor cell migration in vitro and
prostate cancer in vivo
In vitro, in vivo
(mice) PC-3 Doxazosin
Doxazosin induced cell rounding and detachment via agonistic actions on
EphA2 in vito. Animal studies found that doxazosin reduced number of
tumour metastasis and increased survival in PC-3 xenograft nude mice
[60] Justulin, L. et al.
Combined effect of the finasteride
and doxazosin on rat ventral
prostate morphology and physiology
In vivo PCa Doxazosin andfinasteride
Wistar rats were treated with finasteride and doxazosin and the ventral
prostate was excised at day 3 and day 30.
The combination induced a transient increase in testosterone plasma
concentration and a permanent reduction in DHT. The ventral prostate
and epithelial cell proliferation were reduced and the collagen fibre
volume fraction and apoptosis of the epithelial cell were increased.
Transcription of MMP-2, TIMPs-1 and -2 mRNA was decreased after
30 days of treatment.
[61] Keledjian, K. et al.
Reduction of human prostate tumor
vascularity by the α1-adrenoceptor
antagonist terazosin
In vitro,
retro-spective PCa Terazosin
A significant induction of apoptosis was observed among the cancerous
prostatic epithelial cells in the terazosin-treated, as compared to the
untreated prostate cancer specimens, while there was no significant
change in the proliferative index of the same tumour cell populations
after treatment. Furthermore, terazosin resulted in a significant decrease
in prostate tissue MVD compared with the untreated group, which
correlated with the increased apoptotic index of the cancerous areas.
Tissue PSA expression in the prostatic tumour was also markedly reduced
after terazosin treatment, while no significant changes in VEGF
expression were detected. These findings provide the first evidence that
terazosin; a quinazoline-based α-blocker decreases prostate tumour
vascularity. Our study has significant clinical implications in identifying
selected α-adrenoceptor antagonists as potential anti-tumour agents with
apoptotic and anti-angiogenic effects in the human prostate that can be
exploited for the treatment of advanced prostate cancer.
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[62] Yamada, D. et al.
Reduction of prostate cancer
incidence by naftopidil, an
α1-adrenoceptor antagonist and
transforming growth factor-β
signaling inhibitor
In vitro,
retro-spective PCa
Naftopidil and
tamsulosin
Prostate cancer incidence was significantly lower in men who received
naftopidil for 3 months or longer compared with tamsulosin (p = 0.035).
Immunohistochemically positivity for Bcl2, a marker for resistance to
apoptosis, was less frequently detected in prostate cancer cells of men
who received naftopidil compared with tamsulosin. Naftopidil induced
apoptosis and blocked Smad2 phosphorylation activated by transforming
growth factor-B in cell lines.
[63] Tahmat-zopoulos, A.
Apoptotic impact of α1-blockers on
prostate cancer growth: a myth or an
inviting reality?
Review, in vitro,
retrospective PCa
Terazosin, doxazosin
and tamsulosin
Description of α-antagonist induced anoikis and angiogenesis. Discusses
retrospective study of patients using terazosin, and marked increase in
tumour vascularity on autopsy.
[64] Bilbro, J. et al.
Therapeutic value of
quinazoline-based compounds in
prostate cancer
Review PCa NA NA
[65] Hui, F. et al.
The α1-adrenergic receptor
antagonist Doxazosin inhibits EGFR
and NF-κB signalling to induce
breast cancer cell apoptosis
In vitro Breast cancer Doxazosin
Doxazosin reduces phosphorylation of EGFR and decreases pERK1/2
levels, NF-κB, AP-1, SRE, E2F and CRE-mediated transcriptional activity.
Doxazosin also decreased phosphorylated retinoblastoma (pRb) protein
expression, providing a potential mechanism for the doxazosin-mediated
G0/G1 cell cycle arrest. Quinazoline ring structure is similar to the EGFR
tyrosine kinase inhibitors. Doxazosin appears to be safe in normal cells
due to the main target being EGFR and NF-κB signalling which has
greater activation in cancer cells.
[66] Park, M. et al.
The antihypertension drug
Doxazosin suppresses JAK/STATs
phosphorylation and enhances the
effects of IFN-α/γ-induced
apoptosis
In vitro, In vivo
(mice) Ovarian cancer Doxazosin
Doxazosin significantly suppressed tumour growth in an ovarian cancer
cell xenograft mouse model (50%–65% reduction in tumour size),
inducing apoptotic cell death by up-regulating the expression of p53.
There was no additional liver toxicity or loss of body weight. In vitro
identified JAK/STAT signaling as potential mediators underlying the
anti-tumour effect of doxazosin.
[67] Kawahara, T. et al.
Silodosin inhibits prostate cancer cell
growth via ELK1 inactivation and
enhances the cytotoxic activity
of gemcitabine
In vitro Prostate Cancer Silodosin andgemcitabine
Silodosin treatment reduced the expression/activity of ELK1 in these cells
as well as viability of AR-positive cells, but not the viability of
AR-negative or ELK1 negative cells. Interestingly silodosin significantly
increased the sensitivity to gemcitabine, but not cisplatin or docetaxel.
ELK1 is likely activated in prostate cancer cells and promote tumour
progression. Furthermore, silodosin that inactivates ELK1 in prostate
cancer cells not only inhibits their growth but also enhances the cytotoxic
activity of gemcitabine. Thus, ELK1 inhibition has the potential of being
a therapeutic approach or prostate cancer.
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[68] Kawahara, T. et al.
Silodosin inhibits the growth of
bladder cancer cells and enhances
the cytotoxic activity of cisplatin via
ELK1 inactivation
In vitro
Bladder Cancer
(ELK-1 positive
urothelial
carcinoma)
Silodosin + cisplatin
Involvement of ELK1 in bladder cancer progression via modulation cell
proliferation/apoptosis, migration and invasion. In bladder and prostate
cancers, ELK1 was shown to induce the proliferation of cells only with
an activated androgen receptor). Silodosin was found to not only inhibit
cell viability and migration, but also enhance the cytotoxic activity of
cisplatin in bladder cancer lines via inactivating ELK1. The results suggest
that combined treatment with silodosin is useful for overcoming
chemoresistance in patients with ELK-1 positive urothelial carcinoma
receiving cisplatin.
[69] Iwamoto, Y. et al.
Oral naftopidil suppresses human
renal-cell carcinoma by inducing
G(1) cell-cycle arrest in tumor and
vascular endothelial cells
In vitro, in vivo
(mice)
Renal Cell
Carcinoma
(ACHN, Caki-2)
ACHN
Naftopidil Naftopidil, but not tamsulosin, was found to inhibit proliferation of renalcancer cells via induction G1 cell cycle arrest in in vitro studies.
[70] Sakamoto, S. et al.
Anoikis disruption of focal
adhesion-Akt signaling impairs
renal cell carcinoma
In vitro Renal cancer786-0, Caki
Doxazosin and
derivatives
Quinazoline-based drugs trigger anoikis in renal cancer cells by targeting
the focal adhesion survival signalling.
[71] Takara, K. et al.
Effects of α-adrenoceptor antagonist
Doxazosin on MDR1-mediated
multidrug resistance and
transcellular transport
In vitro
Human cervical
carcinoma
(HeLa, Hvr100-6)
Doxazosin, prazosin,
terazosin
Co-treatment of chemotheraputics (vinblastine and paclitaxel) with
doxazosin (1 µM) enhanced chemosensitivity of overexpressing
multi-drug resistant HeLa cells, Hvr100-6. On the other hand, prazosin (1
µM) was found to partially reverse cells sensitivity to vinblastine when
used in combination, by dose-dependently increasing intracellular
accumulation of chemotheraputics. Whereas terazosin had no effect. All
other combinations of chemotheraputic and α1-antagonists were found to
have little or no effect on chemosensitivity. Over all this study suggests
that doxazosin thus may partly reverse drug resistance by inhibiting
MDR-1-mediated drug efflux, and in turn, contribute to maintenance of
intracellular cytotoxic concentrations.
[72] Powe, D. et al.
α- And β-adrenergic receptor (AR)
protein expression is associated
with poor clinical outcome in
breast cancer:
an immunohistochemical study
In vitro Breast cancer α-Antagonists α Antagonists were found to inhibit proliferation and induce apoptosisin vitro.
[73] El Sharkawi, F. et al.
Possible anticancer activity of
rosuvastatine, Doxazosin,
repaglinide and oxcarbazepin
In vitro MCF7, HeLa,HepG2,EACC Doxazosin
Doxazosin was most effective in the EACC line exhibiting 100% inhibition
of cell proliferation. Specific mechanisms of action are not reported
or discussed.
[74] Kanno, T. et al.
1-[2-(2-Methoxyphenylamino)
ethylamino]-3-(naphthalene-1-yloxy)
propan-2-ol as a potential
anticancer drug
In vitro
Bladder, prostate,
MPM, lung,
hepatoma, gastric,
renal and
colorectal cancer
cell lines Caco-2
and CW2
Naftopidil This study is discussed in review above. Discuses caspase activation andcell death.
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[75] Kaku, Y. et al.
The newly synthesized anticancer
drug HUHS1015 is useful for
treatment of human gastric cancer
In vitro, in vivo
(mice)
Gastric cancer
(MKN45 and
MKN28)
HUHS1015
(naftopidil analogue)
HUHS1015 treatment caused upregulation of TNFα receptor and
apoptosis was observed in both MKN28 and MKN45. However, no
caspase activation was observed in MKN28, indicating that HUHS1015
resulted in caspase-dependent and independent apoptosis activity. Mice
bearing MKN45 tumours had higher survival rates when treated with
HUHS1015 compared to those treated with cisplatin, paclitaxel
and irinotecan.
[76] Kaku, Y. et al.
HUHS1015 Suppresses Colonic
Cancer Growth by Inducing
Necrosis and Apoptosis in
Association with
Mitochondrial Damage
In vitro, in vivo
(mice)
Colon cancer
(Caco-2, CW2
cells)
HUHS1015
(naftopidil analogue)
HUHS1015 triggered apoptosis in colon cancer Caco-2 and CW2 cells by
disrupting the mitochondrial membrane potential, lowering ATP levels,
cytochrome c release, and initiation of the caspase cascade. In addition,
HUHS1015 increased the number of cells in sub-G1 phase of cell cycling,
which corresponded to apoptosis in both cell lines. In vivo mice studies
demonstrated that treatment with HUHS1015, but not naftopidil, delayed
colonic tumour growth compared to untreated controls. Furthermore, the
authors report 100% survival rate for mice with colonic xenograft tumours
treated with HUHS1015 or naftopidil, which was higher than control
(89% survival).
[77] Shen, S. et al.
Effects of α-adrenoreceptor
antagonists on apoptosis and
proliferation of pancreatic cancer
cells in vitro
In vitro Pancreatic cancer(PC-2 and PC-3)
Yohimbine and
urapidil (α1- and
α2-adrenoreceptor
antagonists)
Yohimbine induced apoptotic cytotoxicity of both pancreatic PC-3 and
PC-3 pancreatic cancer. In contrast, urapidil was only cytotoxic to PC-2
cells. However, the positive control 5-FU, was more cytotoxic than
yohimbine in the conditions tested.
[78] Masachika, E. et al.
Naftopidil induces apoptosis in
malignant mesothelioma cell lines
independently of
α1-adrenoceptor blocking
In vitro Meso-thelialcancer Naftopidil, prazosin
Naftopidil and prazosin both have the potential to induce apoptosis via
activating caspase-3 and caspase-8, but not caspase-9, independent of α1
blocking activity in mesothelioma cells.
[79] Fuchs, R. et al.
The cytotoxicity of the
α1-adrenoceptor antagonist prazosin
is linked to an endocytotic
mechanism equivalent to transport-P
In vitro
K562 cells
erythroleukemia,
LNCaP (PCa)
Prazosin/QAPB
(fluorescent analogue
of prazosin)
Prazosin has been shown to be a substrate for an amine uptake
mechanism called transport-P. The fluorescent analogue of prazosin,
QAPB was associated with endocytic mechanism of prazosin/QAPB
similar transport-P. Prazosin/QAPB was able to induce caspase 8
activation (apoptosis) and tabulation of lysosomes in LNCaP cells.
The cytotoxic actions of prazosin was inhibited by chloroquine
(a lysomototropic drug) and bafilomycin (transport-P inhibitor).
This indicates that transport-p-mediated uptake, and subsequent
endosome/lysosome accumulation and caspase activation underlies
prazosin-induced LNCaP and/or K562 toxicity.
[80] Albinana, V. et al.
Propranolol reduces viability and
induces apoptosis in
hemanglioblastoma cells from von
Hippel-Lindau patients
In vitro
Hemanglio-blastoma,
cervical cancer
HeLa9XHRE
Propranolol
(β-blocker)
Propranolol treatment resulted in cytotoxicity and caspase-mediated
apoptosis (50–100 µM, 48 h treatment) of hypoxia response
element-transfected HeLa 9XHRE cells. Similar findings were also
observed in hemanglioblastoma cells. Overall, the authors suggests these
effects may due in part to the inhibitory effect of HIF1 transcription and
protein expression in HeLA9XHRE and hemanglioblastoma cells.
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[81] Staudacher, I. et al.
HERG K+ channel-dependent
apoptosis and cell cycle arrest in
human glioblastoma cells
In vitro
Glioblastoma
(LNT-229,
U87MG)
Doxazosin, terazosin
Doxazosin was found to induce apoptosis and G0/G1 cell cycle arrest of
glioblastoma LNT-229 and U87MG cells in a time and concentration
dependent manner. Also, blocking of doxazosin binding to hERG by the
non-apoptotic hERG ligand, terazosin, rescued glioblastoma cells from
doxazosin-induced apoptosis. The apoptotic effect of doxazosin was
marked by the activation of pro-apoptotic factors/signalling
(phospho-erythropoietin-producing human hepatocellular carcinoma
receptor tyrosine kinase A2, phospho-p38 mitogen-activated protein
kinase, growth arrest and DNA damage inducible gene 153, cleaved
caspases 9, 7, and 3), and by inactivation of anti- apoptotic
poly-ADP-ribose-polymerase, respectively. Overall, this study suggests
doxazosin is a hERG antagonist, which results in the activation of
apoptotic signaling cascade.
[82] Fuchs, R. et al.
The anti-hypertensive drug prazosin
induces apoptosis in the medullary
thyroid carcinoma cell line TT
In vitro Medullarythyroid carcinoma Prazosin
Prazosin (24 h, ≥15 µM) was found to induce caspase-3/7 activation and
apoptosis of medullary thyroid carcinoma cells (α1A and α1B
adrenoceptors-positive). This cytotoxicity was associated with
morphological changes such as long polar needle-shaped polar protrusion
fibers, an increased in number of intracellular vacuoles and detachment.
The fibres present in treated cells seem to impair mobility of the cell and
were associated with prazosin-mediated caspase activation. Prazosin was
also found to have a similar morphological effect on normal human
fibroblasts, suggesting a lack of specificity and risk of cytotoxicity to
non-cancerous cells.
[83] Tahmatzopoulos, A.et al.
Effect of terazosin on tissue
vascularity and apoptosis in
transitional cell carcinoma of bladder
Observational
Cohort
Transitional cell
carcinoma (TCC)
of the bladder
Terazosin
Pathological specimens of 24 men who underwent radical cystectomy for
transitional cell carcinoma of the bladder were evaluated for
terazosin-induced anti-cancer effects. For this study, patients with a
history of 5a-reductase inhibitor use were excluded. For men who were
never exposed to terazosin (15 men), markers of apoptosis were limited in
the tumour specimens of these men. In contrast, terazosin exposure prior
to cystectomy (9 men, 2–10 mg/day; 3–60 months) was associated with a
statistically significant increase in tumour apoptosis. Terazosin treatment
also significantly decreased microvascular density (MVD) in
approximately 27% of specimens compared to specimens of
unexposed men.
N/A Bajek, A. et al. (2011)
Prostate epithelial stem cells are
resistant to apoptosis after
α1-antagonist treatment. The impact
for BPH patients
In vitro Prostate cancer Doxazosin
Doxazosin induced apoptosis in co-cultures of progenitor (type of stem
cell) and differentiated epithelial cells. However, progenitor cells were not
susceptible to apoptosis, which can be a reason of treatment failure in
BPH patients.
N/A Minarini, A. et al.(2006)
Recent advances in the design and
synthesis of prazosin derivatives - - Found to be irrelevant to our research but still of interest.
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3. Discussion
The overall aim of this literature review was to analyse the current evidence for the clinical use
of α-antagonists as a potential treatment modality for PCa. A summary of results from the sixty-two
studies identified in this systematic review can be found in Table 2.
3.1. In Vitro Evidence
3.1.1. Quinazoline/Piperazine-Dependence
In vitro studies provide substantial evidence that the quinazoline α-antagonists doxazosin,
terazosin and prazosin exhibit cytotoxic activity in the prostate cancer cell lines LNCaP
(androgen-dependent), DU145 and PC-3 (castrate-resistant) cell lines [38–53,84–87]. The structurally
similar piperazine, naftopidil, also produced cytotoxic effects in the androgen-dependent LNCaP and
E9 cell lines [88]. However these effects were not seen with the sulphonamide based tamsulosin [88]
suggesting that the quinazoline/piperazine ring structure maybe responsible for their cytotoxicity
(Figure 1). Furthermore, a number of studies have also investigated the use of doxazosin and naftopidil
analogues, which demonstrated similar cytotoxic potential to the parent drug [54,55,89,90].
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3.1.2. α1-Adrenoceptor-Independence
The mechanisms for cytotoxicity appear to be independent of α1-blockade [39–41] as
demonstrated by several studies, through the use of phenoxybenzamine (a non-selective, irreversible
α-antagonist). Doxazosin and terazosin were observed to reduce cell viability and induce apoptosis in
the presence of phenoxybenzamine [32,38,42,43]. This independent action is supported by two studies
that proposed involvement of the 5HT receptor [44,89] which resulted in reduced cell viability and
apoptosis in PCa.
3.1.3. Cell Death Mechanisms
There are several potential mechanisms accounting for the cytotoxic actions of the
quinazoline/piperazosine α-antagonists, including apoptosis, decreased cell proliferation and
decreased angiogenesis which are crucial mediators of quinazoline-induced cytotoxicity in PCa
cell lines [38]. An illustrative summary of the mechanisms contributing to α-antagonist-induced
cytotoxicity is shown in Figure 2.
Early work by Kyprianou, N. et al. (2000) [32] showed that doxazosin (15 mM) and terazosin
(15 mM) induce apoptosis in a dose dependent manner in PC-3 cell lines using the TUNEL assay [38,42].
As well as inducing apoptosis, doxazosin and terazosin were shown to inhibit cell adhesion to the
extracellular matrix by inducing anoikis. Both agents induced apoptosis in prostate epithelial and
smooth muscle cells at dose ranges used for the treatment of BPH [38]. Similarly Garrison, J. et al.
(2006) [45] proposed that apoptosis was an important mediator of doxazosin-induced cytotoxicity
(at 25 mM/L) in both malignant and benign prostate epithelial cells (PC-3 and BPH-1 cell lines).
These authors suggested that this occurs through increased caspase 8 activation via formation of the
death-inducing signalling complex (DISC) [32,45]. Caspase 8 mediates cell cycle arrest at the G2-M
phase [46], and activates both cleaved caspase 3 and tBid at the BAX/Bak receptor [32,56]. This results
in the release of mitochondrial stress related pro-apoptotic inducing factors including: cytochrome C,
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Smac/diablo, AMID and AIF [29,35,47,91]. More recently, Forbes, A. et al. (2016) [47] found that in PCa
cells, the activation of caspase 3 was similar for prazosin and doxazosin, and suggested superior activity
to terazosin, silodosin and alfuzosin. Prazosin (30 mM) treatment resulted in a six-fold increase in
caspase 3 activation in LNCaP versus a two-fold increase in PC-3 cells suggesting androgen-dependent
prostate cencer (ADPC) cells have greater sensitivity to these effects [47]. Cleaved caspase 3 is used as
a marker for apoptosis [32] and is activated via DISC through FADD recruitment [32,45]. Some studies
support Forbes’ finding of a dose-dependent increase in caspase 3 activation and consequent apoptosis
when treated with quinazolines [32,47,48]. A decrease in HIF-1 (a mediator of resistance) was also
shown in LNCaP cells post quinazoline exposure [47].
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Figure 2. Proposed cytotoxic mechanisms underlying quinazoline-based α-antagonists.
Additionally, α-antagonists exhibit cytotoxicity via cell-cycle arrest. Naftopidil induced G1
cell-cycle arrest in PCa cells in vitro, as did silodosin, but to a lesser extent [88]. Similarly, prazosin and
doxazosin caused an increase in DNA strand breakage leading to subsequent G2 cell-cycle arrest and
apoptosis, possibly through the inactivation of CDK1 [46,57]. Ho, C. et al. (2015) [58] showed that the
reversible non-selective α-antagonist, phentolamine (an imidazoline), caused cell-cycle arrest in CRPC
cells by inducing microtubule assembly, leading to mitotic arrest of the cell-cycle and mitochondrial
damage. This inhibition of mitosis is a similar chemotherapeutic mechanism to taxanes [59]. It was
suggested that disruption of the cell-cycle by quinazolines can be explained by competitive inhibition
of the ATP attachment of tyrosine kinase and inhibiting phosphorylation of PI3K from the following
receptors: HER2/Neu, EGF, and VEGF [32,60]. These receptors are well-identified targets of current
chemotherapeutic agents, such as bevacizumab which targets VEGF.
Another proposed mechanism underlying the cytotoxic actions of α-antagonists is disruption
of DNA integrity. Desiniotis, A. et al. (2011) [32] suggested that quinazolines derivatives cause
DNA intercalation, similar to anthracycline chemotherapeutics. DNA fragmentation was also
observed in studies that tested doxazosin (25 mM) [32,49]. Doxazosin is proposed to inhibit
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topoisomerase 1, inducing DNA damage and resulting in synergistic cytotoxic activity with etoposide
and adriamycin [86]. Furthermore, apoptosis and cell-cycle arrest lead to decreased cell growth and
proliferation of PCa cells. This leads to decreased cell survival, migration and adhesion resulting in
anoikis [50,61,90].
In vitro evidence also suggests that quinazolines have the potential to disrupt key mediators
of angiogenesis. Quinazolines downregulate VEGF, resulting in reduced repression of TGF-β
receptor [32,51,60]. TGF-β is responsible for the transcription of various apoptosis factors as well
as increasing IκBα; the inhibitor of NF-κB [32,60]. Forbes, A. et al. (2016) [51] noted an increase in
stress related factors such as p38α and MAPKs in PCa cells treated with α-antagonists [47], which
is suggestive of TGF-β activation. The α-antagonist-mediated disruption and down-regulation of
VEGF results in decreased angiogenesis by increasing apoptosis and anoikis [32,52,61]. The inhibition
of this signalling pathway blocks Bcl-2, an anoikis inhibiting factor that is identified in CRPC and is
a mediator for cell immunity via bypass pathway mutations [32,52]. Targeting this factor improves
selectivity and may improve treatment outcomes in CRPC. This was observed in prostate cells, where
treatment with doxazosin resulted in inhibition of VEGF-induced angiogenesis, reduced cell migration
and increased cell death due to anoikis [53,61], possibly via EphA2 agonist activity [62].
3.2. In Vivo Evidence
Consistent with in vitro studies, the ability of quinazoline α-antagonists to reduce tumour
growth and potentially decrease angiogenesis is also observed in mice models of PCa. PCa
xenografts in mice showed that tumour mass was significantly reduced when treated with quinazoline
compounds prazosin and doxazosin compared to untreated controls, possibly through the induction
of apoptosis [38,42,46,57,62]. Terazosin treatment in nude mice significantly reduced VEGF induced
angiogenesis. This effect was also seen in prostate tumour mice models [39] suggesting that terazosin
has very potent anti-angiogenic effects, reducing tumour volume over time. Anti-proliferative effects of
doxazosin were also observed in Wistar rats treated with doxazosin and finasteride [63]. Interestingly,
doxazosin has recently been identified as a novel EphA2 agonist [47,62], which triggers PCa cytotoxicity
via cell rounding and detachment in vitro and this mechanism may translate to animal models [62].
In line with previous in vivo studies, doxaozisn was previously found to reduce tumour metastasis
and improve survival of PC-3 xenograft nude mice. These anti-tumour effects were proposed to occur,
to some extent, by EphA2-mediated cell detachment, inhibition of tumour cell migration [62], and
indirect activation of apoptosis.
3.3. Clinical Evidence
To determine if the cytotoxic and anti-tumour effects observed in vitro and in mice models
translate into a potential therapeutic application in human patients, we examined their effects in
patients taking them long term (ranging from 3 to 11 months or longer) [34,36]. However, to date
there are only four retrospective human studies that have investigated the benefit of quinazoline based
α-antagonists in patients after original treatment ended (Table 1). Interestingly, both quinazoline
and non-quinazoline α-antagonists appear to decrease the incidence of PCa at doses indicated for
the symptomatic relief of LUTs [35–37,64]. It is therefore difficult to evaluate their potential for
treating PCa.
3.4. Anticancer Effects of α-Antagonists in Other Cancers
Lastly, we examined the potential of cytotoxic and antitumor actions of α-antagonists in other
cancers (See Table 2 and Supplementary Material Figure S1 for detailed review). Consistent with
in vitro and in vivo animal findings in PCa, classical α-antagonists and their analogues appear to
have broad activity, exhibiting cytotoxicity in other cancer cell lines including urogenital [44,65–74],
gastrointestinal [73–77], lung [74,78], blood [79], brain [80,81] and thyroid [82]. Importantly, the
cytotoxic and anti-proliferative effects are supported by several in vivo mice studies [48,66], suggesting
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ubiquitous anticancer actions of these drugs. In support of in vitro findings a retrospective study in
24 patients with bladder cancer, 15 of which had been treated with terazosin over a 3–6 month period,
had a reduction in incidence, tissue MVD and increase in apoptotic index [83]. The only trials with
doses that are of clinical relevance are with bladder, pituitary and ovarian cancer, all of which are
within the standard dosage ranges of the respective medications [48,50,66]. The proposed cytotoxic
mechanisms of α-antagonists in other cancers differ from those identified in PCa, suggesting the
magnitude of their anticancer effects may vary between cancer types. It is difficult to draw sound
conclusions of the efficacy of α-antagonists in other cancers from this data.
4. Conclusions
PCa is the most commonly diagnosed cancer in Australia with substantial mortality associated
with the castrate resistant form. Current treatments are significantly limited by the development of
resistance, as well as severe toxicity. Therefore, there is an urgent need to identify alternate or adjunct
treatment options. Given their key role in managing the LUTs associated with PCa and its treatments,
as well as in vitro cytotoxicity against PCa cell lines, α-antagonists may offer such a treatment option.
However, apart from a series of excellent in vitro studies and limited animal studies, the potential of
α-antagonists as a treatment option in human patients remains unclear. Therefore, the purpose of this
literary review was to analyse the current evidence for the use of α-antagonists in the treatment of
prostate and other cancers, and elucidate mechanisms responsible for their cytotoxic effects.
Several elegant in vitro studies demonstrate that quinazoline based α-antagonists (doxazosin,
terazosin and prazosin) are cytotoxic to PCa cell lines by inducing apoptosis, inhibiting cell proliferation
and angiogenesis. Similarly, these effects were also observed with the piperazine based agent naftopidil.
In contrast tamsulosin, a sulphonamide based compound did not exhibit cytotoxic activity, suggesting
that structural specificity is important in eliciting cytotoxic action. In vitro studies also suggest that
the quinazoline α-antagonists may also target angiogenesis by disrupting VEGF. Furthermore, several
studies also suggest that the cytotoxic actions are not limited to PCa cell lines as α-antagonists were
also shown to induce cell death in some of the following cell lines: Bladder HT1376, Ovarian SKOV-3,
Renal Carcinoma ACHN and Caki-2. However, more robust trials with standardised methodologies
are required to strengthen the evidence of α-antagonists as chemotherapeutic agents in cancers other
than prostate.
The in vitro findings are reflected in mice models of PCa, with many studies showing that tumour
growth and angiogenesis is significantly decreased when animals are treated with quinazoline or
piperazine agents. However, evidence for the potential of the quinazoline and piperazine α-antagonists
to treat PCa in human patients is lacking. We identified only four studies looking at the risk of
developing PCa in human patients using α-antagonists. These retrospective and observational cohort
studies did not examine the potential of these agents to treat PCa. Instead, they showed a decreased
incidence of PCa in long term users of α-antagonists.
Therefore, while the in vitro and animal studies clearly demonstrate the potential role of
quinazoline and piperazine based α-antagonists in the treatment of prostate and other cancers, well
designed, prospective clinical trials in humans are required to ultimately evaluate their efficacy as
either a primary treatment option or as an adjunct. It is difficult to draw sound conclusions of
the efficacy of α-antagonists in other cancers from the data analysed in this review. More robust
trials with standardised methodologies are required to strengthen the evidence of α-antagonists as
chemotherapeutic agents in cancers other than prostate. We hope the findings from this literature
review will stimulate further research to potentially place α-antagonists as possible treatment options
for PCa in the future.
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Appendix A
Table A1. Inclusion/exclusion search terms/filters included in methodology.
Search Term 1: Agent Search Term 2: Target Tissue Search Term 3: Action
Alfuzosin
α Adrenergic antagonist
α Adrenoreceptor blockers
α Blocker
Doxazosin
Naftopidil
Phentolamine
Prazosin
Silodosin
Terazosin
Adenocarcinoma
Cancer
Carcinoma
Neoplasm
Prostate cancer
Anoikis
Anti-angiogenic
Anti-proliferative
Anticancer
Antineoplastic
Apoptosis
Cytotoxic
Filters Applied in PubMed
Text—Full text
Publication Date—2000–2016
Language—English
Subjects—Cancer
Search Fields—Title/Abstract
Exclusion terms: In Title/Abstract
AG1478, α-methyl-DL-tryptophan, α-linolenic, α-methyltryptophan, Biscoumarins, BYL719, Calcium
channels, Cardiotoxic, Chitosan, Gambogic acid, Glyceollin, Hepatocarcinogens, HhAntag691, Insulin-like
growth factor 1 receptor, LSC, Mast cells, PSC833, R482G isoform, Raloxifene, Stapling, Stilbenes, Toremifene,
Triphosphate-binding
Combined Search Terms
(α adrenergic antagonist OR α adrenoreceptor blocker OR α blocker OR Prazosin OR Doxazosin OR
Naftopidil OR Phentolamine OR Alfuzosin OR Terazosin OR Silodosin) AND (Neoplasm OR Cancer OR
Prostate cancer OR Carcinoma OR Adenocarcinoma) AND (Anoikis OR Antineoplastic OR Apoptosis OR
Anticancer OR Anti-angiogenic OR Anti-proliferative OR Cytotoxic) NOT (Calcium channels OR Cardiotoxic
OR LSC OR Biscoumarins OR Glyceollin OR Chitosan OR toremifene OR triphosphate-binding OR α-linolenic
OR α-methyl-DL-tryptophan OR HhAntag691 OR α-methyltryptophan OR raloxifene OR AG1478 OR R482G
isoform OR PSC833 OR Mast cells OR Gambogic acid OR hepatocarcinogens OR insulin-like growth factor 1
receptor OR stapling OR BYL719 OR stilbenes)
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